144 related articles for article (PubMed ID: 36672633)
1. Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer.
Napier TS; Lynch SE; Lu Y; Song PN; Burns AC; Sorace AG
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672633
[TBL] [Abstract][Full Text] [Related]
2. Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer.
Napier TS; Hunter CL; Song PN; Larimer BM; Sorace AG
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214172
[TBL] [Abstract][Full Text] [Related]
3. Reduction of tumor hypoxia by anti-PD-1 therapy assessed using pimonidazole and [
Nakajima K; Homma M; Suzuki M; Yokouchi Y; Matsuda T; Takakura H; Hirata K; Kuge Y; Ogawa M
Nucl Med Biol; 2022; 108-109():85-92. PubMed ID: 35367730
[TBL] [Abstract][Full Text] [Related]
4. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
[TBL] [Abstract][Full Text] [Related]
5.
Reeves KM; Song PN; Angermeier A; Della Manna D; Li Y; Wang J; Yang ES; Sorace AG; Larimer BM
Clin Cancer Res; 2022 Jan; 28(2):327-337. PubMed ID: 34615724
[TBL] [Abstract][Full Text] [Related]
6. [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
Raccagni I; Belloli S; Valtorta S; Stefano A; Presotto L; Pascali C; Bogni A; Tortoreto M; Zaffaroni N; Daidone MG; Russo G; Bombardieri E; Moresco RM
PLoS One; 2018; 13(5):e0197754. PubMed ID: 29791503
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
8. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Murakami M; Zhao S; Zhao Y; Chowdhury NF; Yu W; Nishijima K; Takiguchi M; Tamaki N; Kuge Y
Int J Oncol; 2012 Nov; 41(5):1593-600. PubMed ID: 22965141
[TBL] [Abstract][Full Text] [Related]
9.
Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
[TBL] [Abstract][Full Text] [Related]
10.
Maruyama K; Okada T; Ueha T; Isohashi K; Ikeda H; Kanai Y; Sasaki K; Gentsu T; Ueshima E; Sofue K; Nogami M; Yamaguchi M; Sugimoto K; Sakai Y; Hatazawa J; Murakami T
Oncol Lett; 2021 Mar; 21(3):207. PubMed ID: 33574946
[TBL] [Abstract][Full Text] [Related]
11.
Quintela-Fandino M; Lluch A; Manso L; Calvo I; Cortes J; García-Saenz JA; Gil-Gil M; Martinez-Jánez N; Gonzalez-Martin A; Adrover E; de Andres R; Viñas G; Llombart-Cussac A; Alba E; Guerra J; Bermejo B; Zamora E; Moreno-Anton F; Pernas Simon S; Carrato A; Lopez-Alonso A; Escudero MJ; Campo R; Carrasco E; Palacios J; Mulero F; Colomer R
Clin Cancer Res; 2017 Mar; 23(6):1432-1441. PubMed ID: 27587436
[No Abstract] [Full Text] [Related]
12. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
13. Mathematical Model of Triple-Negative Breast Cancer in Response to Combination Chemotherapies.
Davenport AA; Lu Y; Gallegos CA; Massicano AVF; Heinzman KA; Song PN; Sorace AG; Cogan NG
Bull Math Biol; 2022 Dec; 85(1):7. PubMed ID: 36542180
[TBL] [Abstract][Full Text] [Related]
14. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
15.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
Anticancer Res; 2023 Jan; 43(1):127-136. PubMed ID: 36585209
[TBL] [Abstract][Full Text] [Related]
16. Monitoring CD8a
Kristensen LK; Christensen C; Alfsen MZ; Cold S; Nielsen CH; Kjaer A
Mol Imaging Biol; 2020 Aug; 22(4):1021-1030. PubMed ID: 32086762
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three
Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
[TBL] [Abstract][Full Text] [Related]
18. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
Deng J; Thennavan A; Shah S; Bagdatlioglu E; Klar N; Heguy A; Marier C; Meyn P; Zhang Y; Labbe K; Almonte C; Krogsgaard M; Perou CM; Wong KK; Adams S
Breast Cancer Res Treat; 2021 Jan; 185(1):85-94. PubMed ID: 32949350
[TBL] [Abstract][Full Text] [Related]
19. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
20. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
